Orexo submits NDA for Zubsolv for opiod dependence

Friday, September 7, 2012 01:41 PM

Orexo, an emerging specialty pharmaceutical company, has submited a New Drug Application (NDA) for a novel combination product of buprenorphine and naloxone for treatment of opioid dependence, a condition affecting over two million Americans.

The development of Zubsolv (OX219), a product based on Orexo’s proprietary sublingual drug delivery technology, has progressed well and faster than originally anticipated. A total of four clinical studies were completed in support of the filing, along with a CMC product stability program covering two independent manufacturing sites.

“Today´s FDA submission, the third in our short history, constitutes a substantial milestone,” said Anders Lundström, CEO of Orexo. “Very few companies of our size and lifetime have ever managed to complete three development programs, Edluar, Abstral and now Zubsolv. Orexo will potentially be the first company to offer an alternative treatment option to Suboxone, which reached sales of $1.3 billion in 2011 and continues to exhibit steady growth of more than 15% annually.”

Lundström continued, “The earlier submission is expected to be of major commercial importance, as it provides a potential launch of Zubsolv in the third quarter of 2013—ahead of other branded competitors.

The Zubsolv treatment option will, once approved by the FDA, be directed towards the authorized specialized prescribers of Suboxone in U.S., of which 5,000 physicians account for about 90% of all U.S. prescriptions.

“In our clinical studies Zubsolv has demonstrated an accelerated dissolve time, has a smaller tablet size and an improved taste, resulting in a strong preference in comparison with the Suboxone tablet,” said Lundström. “Our market insights indicate that these properties, which are important product characteristics for particularly sublingual therapies, will be important drivers for the market uptake of the product and we estimate peak sales to reach $500 million annually.”  

The NDA submission for Zubsolv was five months ahead of schedule. Orexo will now finalize its U.S. commercialization plans for the brand.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs